Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 5

Obstructive sleep apnea and bone mineral density in obese patients

Authors Mariani S, Fiore D, Varone L, Basciani S, Persichetti A, Watanabe M, Saponara M, Spera G, Moretti C, Gnessi L

Published Date November 2012 Volume 2012:5 Pages 395—401

DOI http://dx.doi.org/10.2147/DMSO.S37761

Received 5 September 2012, Accepted 26 September 2012, Published 7 November 2012

Stefania Mariani,1 Daniela Fiore,1 Laura Varone,2 Sabrina Basciani,1 Agnese Persichetti,1 Mikiko Watanabe,1 Maurizio Saponara,3 Giovanni Spera,1 Costanzo Moretti,4 Lucio Gnessi1

1Department of Experimental Medicine, Section of Medical Physiopathology and Endocrinology, Sapienza University of Rome, Italy; 2Department of Environmental Biology, Sapienza University of Rome, Italy; 3Department of Otolaryngology, Audiology and Phonation, Sapienza University of Rome, Italy; 4Division of Endocrinology, Department of System Medicine, Section of Reproductive Endocrinology University of TorVergata, Fatebenefratelli Hospital "San Giovanni Calibita" Rome, Italy

Context: Obesity and its co-morbidities may adversely affect bone mineral density (BMD). Obstructive sleep apnea (OSA) is a major complication of obesity. To date, the effects of OSA on BMD in obese patients have been poorly studied.
Objective: To examine whether the severity of OSA independently correlates with BMD in obese patients.
Methods: One hundred and fifteen obese subjects with OSA (Apnea/Hypopnea Index [AHI] ≥5 events per hour) were included in the study. BMD was measured at lumbar spine, total hip, and femoral neck by dual energy X-ray absorptiometry. Body mass index, lean mass, and representative measures of metabolic syndrome (waist circumference, fasting plasma glucose, blood pressure, HDL-cholesterol, triglycerides) and inflammation (ESR, CRP, fibrinogen) were also evaluated.
Results: BMD did not differ among obese individuals regardless of OSA severity. Correlation coefficient analysis for all the covariates showed a lack of association between AHI and BMD that was strongly influenced by age and weight.
Conclusion: Our study does not support an independent association between AHI and BMD in obese patients. Controlled studies involving a greater number of patients are warranted.

Keywords: obesity, polysomnography, metabolic syndrome

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults

Da Costa LA, Arora P, García-Bailo B, Karmali M, El-Sohemy A, Badawi A

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012, 5:347-355

Published Date: 4 October 2012

Development of single-port cholecystectomy: results of a case-control study matched to one surgeon

Wawra N, Buia A, Hanisch E

Open Access Surgery 2012, 5:33-38

Published Date: 7 November 2012

Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, Mexico

García-Alcalá H, Genestier-Tamborero CN, Hirales-Tamez O, Salinas-Palma J, Soto-Vega E

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012, 5:403-406

Published Date: 19 November 2012

Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis

Miyoshi S, Hamada H, Ito R, Katayama H, Irifune K, Suwaki T, Nakanishi N, Kanematsu T, Dote K, Aibiki M, Okura T, Higaki J

Drug Design, Development and Therapy 2013, 7:305-316

Published Date: 10 April 2013

Polyethylenimine600-β-cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells

Tong H, Wang C, Huang Y, Shi Q, Fernandes JC, Dai K, Tang G, Zhang X

International Journal of Nanomedicine 2013, 8:1935-1946

Published Date: 24 May 2013

Lorcaserin for weight management

Taylor JR, Dietrich E, Powell J

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:209-216

Published Date: 13 June 2013